TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA
NYSE · XNYS · stock · Pharmaceutical Preparations
Chart by TradingView
7/9
Piotroski F — financial health
-0.41
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $17.3B | $1.4B | $8.9B | — | $7.9B |
| 2024 | $16.5B | -$1.6B | $8.1B | — | $5.4B |
| 2023 | $15.8B | -$559.0M | $7.6B | — | $8.1B |
| 2022 | $14.9B | -$2.4B | $7.0B | $1.0B | $8.6B |
| 2021 | $15.9B | $417.0M | $7.6B | $236.0M | $11.2B |
| 2020 | $16.7B | -$4.0B | $7.7B | $638.0M | $11.1B |
Why these scores methodology →
Piotroski F-score: 7/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -0.41 (distress)
- Working capital / assets 0.012
- Retained earnings / assets -0.338
- EBIT / assets 0.053
- Equity / liabilities 0.241
Source: SEC EDGAR filings · CIK 0000818686 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.